Federated Investors Inc. PA lifted its holdings in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 4,792.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,360 shares of the company’s stock after buying an additional 6,230 shares during the quarter. Federated Investors Inc. PA’s holdings in Aerie Pharmaceuticals were worth $334,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AERI. Quantbot Technologies LP purchased a new stake in shares of Aerie Pharmaceuticals in the 1st quarter worth about $107,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Aerie Pharmaceuticals in the 1st quarter worth about $108,000. BNP Paribas Arbitrage SA grew its position in shares of Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after buying an additional 3,579 shares during the period. BlueCrest Capital Management Ltd purchased a new stake in shares of Aerie Pharmaceuticals in the 1st quarter worth about $202,000. Finally, Palisade Capital Management LLC NJ purchased a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter worth about $212,000. 94.64% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Aerie Pharmaceuticals, Inc. (NASDAQ AERI) opened at 50.95 on Friday. The stock’s market cap is $1.85 billion. The stock’s 50 day moving average is $54.83 and its 200-day moving average is $50.04. Aerie Pharmaceuticals, Inc. has a one year low of $32.05 and a one year high of $61.30.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.02. On average, equities analysts forecast that Aerie Pharmaceuticals, Inc. will post ($2.59) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/23/federated-investors-inc-pa-acquires-6230-shares-of-aerie-pharmaceuticals-inc-aeri.html.

A number of analysts have recently weighed in on AERI shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 target price on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Mizuho reaffirmed a “buy” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Wednesday. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Finally, HC Wainwright set a $69.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $66.36.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.